RGNX

REGENXBIO Inc.

Price Chart

Latest Quote

$7.80

-0.10 (-1.27%)

Current Price

Previous Close	$7.90
Open	$8.20
Day High	$8.57
Day Low	$7.78
Volume	3,205,429

Fetched: 2026-06-21T10:53:17

Stock Information

Shares Outstanding	51.70M
Total Debt	$248.40M
Cash Equivalents	$150.49M
Revenue	$87.82M
Net Income	$-290.01M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$403.24M
EPS (TTM)	$-5.60
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$501.15M
Sales	$87.82M
Income	$-290.01M
Book/sh	$0.41
Cash/sh	$2.91
Employees	371

Financial Ratios

Quick Ratio	2.44
Current Ratio	2.62
Debt/Eq	1178.24

Returns & Margins

ROA	-38.53%
ROE	-196.43%
Gross Margin	-196.61%
Operating Margin	-1303.96%

Ownership

Insider Ownership	8.07%
Institutional Ownership	84.71%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-2.85
P/S	4.59
P/B	19.12

Analyst Data

Recommendation	buy
Target Price	$23.82

Technical Indicators

SMA20	$6.73
SMA50	$7.95
SMA200	$10.34
RSI	58.72
ATR	0.6013

Shares Float	43.03M
Short Float	17.23%
Short Ratio	4.24
Volatility	1.03
Rel Volume	1.88

Performance History

Week	+24.20%
Month	+37.81%
Quarter	-6.70%
6 Months	-44.72%
YTD	-42.52%
Year	-9.93%
3 Years	-61.44%
5 Years	-79.30%
10 Years	-18.92%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$7.80	3,205,400
2026-06-17	$7.90	4,964,700
2026-06-16	$6.93	967,400
2026-06-15	$7.07	1,642,400
2026-06-12	$6.66	903,500
2026-06-11	$6.28	1,393,700
2026-06-10	$6.13	821,900
2026-06-09	$6.34	1,987,000
2026-06-08	$6.13	1,198,000
2026-06-05	$6.08	1,699,300
2026-06-04	$6.88	1,253,400
2026-06-03	$6.69	1,284,800
2026-06-02	$6.52	1,501,700
2026-06-01	$7.14	1,160,700
2026-05-29	$7.01	1,126,900
2026-05-28	$6.89	1,518,900
2026-05-27	$6.69	1,534,500
2026-05-26	$6.31	1,421,400
2026-05-22	$6.35	1,569,400
2026-05-21	$6.75	2,972,700
2026-05-20	$5.97	2,246,600
2026-05-19	$5.66	1,784,700

About REGENXBIO Inc.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

📰 Latest News

Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says

MT Newswires • 2026-06-18T15:04:44Z

Are Options Traders Betting on a Big Move in REGENXBIO Stock?

Zacks • 2026-06-16T14:24:00Z

Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care

Zacks • 2026-06-03T15:50:00Z

How The REGENXBIO (RGNX) Investment Story Is Evolving Without New Analyst Commentary

Simply Wall St. • 2026-06-02T00:21:44Z

Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway

Insider Monkey • 2026-05-20T12:35:43Z

Regenxbio (RGNX) Q1 2026 Earnings Transcript

Motley Fool • 2026-05-18T13:06:27Z

Regenxbio Inc (RGNX) Q1 2026 Earnings Call Highlights: Promising RGX-202 Results and Path to ...

GuruFocus.com • 2026-05-14T23:03:27Z

Update: Regenxbio Shares Fall After Q1 Swings to Loss, Revenue Declines; Phase 3 Study of RGX-202 Meets Primary Endpoint

MT Newswires • 2026-05-14T18:39:29Z

Regenxbio Shares Rise After Positive Duchenne Trial Results

InvestorsHub • 2026-05-14T14:09:48Z

Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates

Zacks • 2026-05-14T12:30:03Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$20,298,000	$33,567,000	$37,213,000	$54,545,000
Cost Of Revenue	$20,298,000	$33,567,000	$37,213,000	$54,545,000
Total Revenue	$170,441,000	$83,328,000	$90,242,000	$112,724,000
Operating Revenue	$170,441,000	$83,328,000	$90,242,000	$112,724,000
Expenses
Interest Expense	$45,008,000	$12,659,000	$6,862,000	$23,254,000
Total Expenses	$331,639,000	$314,573,000	$358,370,000	$375,600,000
Other Income Expense	$12,245,000	$16,628,000	$11,319,000	$5,383,000
Net Non Operating Interest Income Expense	$-44,925,000	$-12,485,000	$-6,837,000	$-22,912,000
Interest Expense Non Operating	$45,008,000	$12,659,000	$6,862,000	$23,254,000
Operating Expense	$311,341,000	$281,006,000	$321,157,000	$321,055,000
Other Operating Expenses	$179,000	$865,000	$397,000	$-6,679,000
General And Administrative Expense	$82,863,000	$76,619,000	$88,494,000	$85,281,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-193,878,000	$-227,102,000	$-263,494,000	$-280,321,000
Net Interest Income	$-44,925,000	$-12,485,000	$-6,837,000	$-22,912,000
Interest Income	$83,000	$174,000	$25,000	$342,000
Normalized Income	$-206,123,000	$-243,730,000	$-274,806,474	$-285,702,387
Net Income From Continuing And Discontinued Operation	$-193,878,000	$-227,102,000	$-263,494,000	$-280,321,000
Total Operating Income As Reported	$-161,198,000	$-233,346,000	$-268,128,000	$-262,876,000
Net Income Common Stockholders	$-193,878,000	$-227,102,000	$-263,494,000	$-280,321,000
Net Income	$-193,878,000	$-227,102,000	$-263,494,000	$-280,321,000
Net Income Including Noncontrolling Interests	$-193,878,000	$-227,102,000	$-263,494,000	$-280,321,000
Net Income Continuous Operations	$-193,878,000	$-227,102,000	$-263,494,000	$-280,321,000
Pretax Income	$-193,878,000	$-227,102,000	$-263,646,000	$-280,405,000
Special Income Charges	$0	$-2,101,000	$0	$0
Interest Income Non Operating	$83,000	$174,000	$25,000	$342,000
Operating Income	$-161,198,000	$-231,245,000	$-268,128,000	$-262,876,000
Gross Profit	$150,143,000	$49,761,000	$53,029,000	$58,179,000
Per Share
Diluted EPS	$-3.76	$-4.59	$-6.02	$-6.50
Basic EPS	$-3.76	$-4.59	$-6.02	$-6.50
Other
Tax Effect Of Unusual Items	$0	$0	$6,526	$1,613
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-145,500,000	$-214,856,000	$-250,783,000	$-249,625,000
Total Unusual Items	$12,245,000	$16,628,000	$11,319,000	$5,383,000
Total Unusual Items Excluding Goodwill	$12,245,000	$16,628,000	$11,319,000	$5,383,000
Reconciled Depreciation	$15,615,000	$16,215,000	$17,320,000	$12,909,000
EBITDA (Bullshit earnings)	$-133,255,000	$-198,228,000	$-239,464,000	$-244,242,000
EBIT	$-148,870,000	$-214,443,000	$-256,784,000	$-257,151,000
Diluted Average Shares	$51,573,000	$49,509,000	$43,734,000	$43,152,000
Basic Average Shares	$51,573,000	$49,509,000	$43,734,000	$43,152,000
Diluted NI Availto Com Stockholders	$-193,878,000	$-227,102,000	$-263,494,000	$-280,321,000
Impairment Of Capital Assets	$0	$2,101,000	$0	$0
Gain On Sale Of Security	$12,245,000	$18,729,000	$11,319,000	$5,383,000
Provision For Doubtful Accounts	$0	$-5,000,000	$0	$0
Research And Development	$228,299,000	$208,522,000	$232,266,000	$242,453,000
Selling General And Administration	$82,863,000	$76,619,000	$88,494,000	$85,281,000
Other Gand A	$82,863,000	$76,619,000	$88,494,000	$85,281,000
Tax Provision	-	$0	$-152,000	$-84,000

Fetched: 2026-06-17

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$102,733,000	$259,651,000	$311,742,000	$516,195,000
Total Assets	$453,032,000	$465,989,000	$573,970,000	$833,268,000
Total Non Current Assets	$171,751,000	$187,988,000	$238,999,000	$417,292,000
Other Non Current Assets	$6,643,000	$6,030,000	$6,837,000	$8,427,000
Non Current Accounts Receivable	$2,312,000	$474,000	$701,000	$1,504,000
Investmentin Financial Assets	$10,785,000	$10,179,000	$38,871,000	$200,560,000
Current Assets	$281,281,000	$278,001,000	$334,971,000	$415,976,000
Other Current Assets	$11,901,000	$12,680,000	$18,852,000	$7,142,000
Prepaid Assets	$11,927,000	$9,067,000	$14,520,000	$13,900,000
Receivables	$27,383,000	$21,567,000	$26,341,000	$30,292,000
Other Receivables	$25,822,000	$20,408,000	$24,525,000	$27,802,000
Accrued Interest Receivable	$1,004,000	$1,094,000	$1,551,000	$2,210,000
Accounts Receivable	$557,000	$65,000	$4,852,000	$280,000
Gross Accounts Receivable	$557,000	$65,000	$4,852,000	$280,000
Cash Cash Equivalents And Short Term Investments	$230,070,000	$234,687,000	$275,258,000	$364,642,000
Cash And Cash Equivalents	$34,466,000	$57,526,000	$34,522,000	$96,952,000
Receivables Adjustments Allowances	-	$0	$-4,587,000	$0
Allowance For Doubtful Accounts Receivable	-	-	$-4,587,000	$0
Debt
Total Debt	$73,501,000	$82,033,000	$89,290,000	$94,799,000
Long Term Debt And Capital Lease Obligation	$65,215,000	$74,131,000	$82,222,000	$88,802,000
Current Debt And Capital Lease Obligation	$8,286,000	$7,902,000	$7,068,000	$5,997,000
Liabilities
Total Liabilities Net Minority Interest	$350,299,000	$206,338,000	$262,228,000	$317,073,000
Total Non Current Liabilities Net Minority Interest	$232,204,000	$103,144,000	$131,956,000	$186,639,000
Other Non Current Liabilities	$148,046,000	$29,013,000	$49,734,000	$97,837,000
Non Current Deferred Liabilities	$18,943,000	$0	-	-
Current Liabilities	$118,095,000	$103,194,000	$130,272,000	$130,434,000
Other Current Liabilities	$39,609,000	$34,309,000	$50,567,000	$48,601,000
Current Deferred Liabilities	$10,452,000	$115,000	$148,000	$1,829,000
Payables And Accrued Expenses	$42,330,000	$43,261,000	$54,343,000	$55,936,000
Payables	$21,358,000	$22,798,000	$22,786,000	$27,213,000
Accounts Payable	$21,358,000	$22,798,000	$22,786,000	$27,213,000
Total Tax Payable	-	-	-	$0
Income Tax Payable	-	-	-	$0
Equity
Common Stock Equity	$102,733,000	$259,651,000	$311,742,000	$516,195,000
Total Equity Gross Minority Interest	$102,733,000	$259,651,000	$311,742,000	$516,195,000
Stockholders Equity	$102,733,000	$259,651,000	$311,742,000	$516,195,000
Gains Losses Not Affecting Retained Earnings	$-687,000	$-741,000	$-4,429,000	$-15,401,000
Retained Earnings	$-1,126,027,000	$-932,149,000	$-705,047,000	$-441,553,000
Other
Ordinary Shares Number	$50,892,000	$49,549,399	$44,046,242	$43,299,000
Share Issued	$50,892,000	$49,549,399	$44,046,242	$43,299,000
Tangible Book Value	$102,733,000	$259,651,000	$311,742,000	$516,195,000
Invested Capital	$102,733,000	$259,651,000	$311,742,000	$516,195,000
Working Capital	$163,186,000	$174,807,000	$204,699,000	$285,542,000
Capital Lease Obligations	$73,501,000	$82,033,000	$89,290,000	$94,799,000
Total Capitalization	$102,733,000	$259,651,000	$311,742,000	$516,195,000
Additional Paid In Capital	$1,229,442,000	$1,192,536,000	$1,021,214,000	$973,145,000
Capital Stock	$5,000	$5,000	$4,000	$4,000
Common Stock	$5,000	$5,000	$4,000	$4,000
Preferred Stock	$0	$0	$0	$0
Non Current Deferred Revenue	$18,943,000	$0	-	-
Long Term Capital Lease Obligation	$65,215,000	$74,131,000	$82,222,000	$88,802,000
Current Deferred Revenue	$10,452,000	$115,000	$148,000	$1,829,000
Current Capital Lease Obligation	$8,286,000	$7,902,000	$7,068,000	$5,997,000
Pensionand Other Post Retirement Benefit Plans Current	$17,418,000	$17,607,000	$18,146,000	$18,071,000
Current Accrued Expenses	$20,972,000	$20,463,000	$31,557,000	$28,723,000
Investments And Advances	$10,785,000	$10,179,000	$38,871,000	$200,560,000
Available For Sale Securities	$10,785,000	$10,179,000	$38,871,000	$200,560,000
Net PPE	$152,011,000	$171,305,000	$192,590,000	$206,801,000
Accumulated Depreciation	$-87,192,000	$-72,292,000	$-57,208,000	$-41,388,000
Gross PPE	$239,203,000	$243,597,000	$249,798,000	$248,189,000
Leases	$101,610,000	$101,465,000	$101,927,000	$99,397,000
Other Properties	$125,981,000	$130,857,000	$136,119,000	$136,917,000
Machinery Furniture Equipment	$11,612,000	$11,275,000	$11,752,000	$11,875,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$195,604,000	$177,161,000	$240,736,000	$267,690,000
Treasury Shares Number	-	-	$0	-

Fetched: 2026-06-17

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-126,377,000	$-175,561,000	$-228,367,000	$-238,212,000
Operating Activities
Operating Cash Flow	$-123,963,000	$-173,125,000	$-218,407,000	$-207,488,000
Cash Flow From Continuing Operating Activities	$-123,963,000	$-173,125,000	$-218,407,000	$-207,488,000
Operating Gains Losses	$-62,000	$-6,616,000	$-2,205,000	$79,000
Investing Activities
Capital Expenditure	$-2,414,000	$-2,436,000	$-9,960,000	$-30,724,000
Investing Cash Flow	$-15,868,000	$103,446,000	$190,943,000	$-11,929,000
Cash Flow From Continuing Investing Activities	$-15,868,000	$103,446,000	$190,943,000	$-11,929,000
Financing Activities
Issuance Of Capital Stock	$1,048,000	$132,258,000	$6,700,000	$1,742,000
Financing Cash Flow	$116,771,000	$92,683,000	$-34,966,000	$-28,840,000
Cash Flow From Continuing Financing Activities	$116,771,000	$92,683,000	$-34,966,000	$-28,840,000
Net Other Financing Charges	$-29,088,000	$-41,087,000	$-43,187,000	$-33,386,000
Net Common Stock Issuance	$1,048,000	$132,258,000	$6,700,000	$1,742,000
Common Stock Issuance	$1,048,000	$132,258,000	$6,700,000	$1,742,000
Other
Issuance Of Debt	$144,493,000	$0	-	-
Interest Paid Supplemental Data	$32,107,000	$6,559,000	$7,276,000	$23,117,000
Income Tax Paid Supplemental Data	$285,000	-	-	$11,812,000
End Cash Position	$36,496,000	$59,556,000	$36,552,000	$98,982,000
Beginning Cash Position	$59,556,000	$36,552,000	$98,982,000	$347,239,000
Changes In Cash	$-23,060,000	$23,004,000	$-62,430,000	$-248,257,000
Proceeds From Stock Option Exercised	$318,000	$1,512,000	$1,521,000	$2,804,000
Net Issuance Payments Of Debt	$144,493,000	$0	-	-
Net Long Term Debt Issuance	$144,493,000	$0	-	-
Long Term Debt Issuance	$144,493,000	$0	-	-
Net Investment Purchase And Sale	$-13,454,000	$105,882,000	$200,903,000	$18,795,000
Sale Of Investment	$319,176,000	$296,021,000	$287,467,000	$203,670,000
Purchase Of Investment	$-332,630,000	$-190,139,000	$-86,564,000	$-184,875,000
Net PPE Purchase And Sale	$-2,414,000	$-2,436,000	$-9,960,000	$-30,724,000
Purchase Of PPE	$-2,414,000	$-2,436,000	$-9,960,000	$-30,724,000
Change In Working Capital	$11,780,000	$5,533,000	$-10,887,000	$13,977,000
Change In Other Working Capital	$29,280,000	$-33,000	$-1,512,000	$-1,165,000
Change In Other Current Liabilities	$-11,622,000	$-10,692,000	$-9,156,000	$7,566,000
Change In Other Current Assets	$6,698,000	$13,514,000	$-3,195,000	$4,728,000
Change In Payables And Accrued Expense	$-2,055,000	$-12,416,000	$-339,000	$-6,826,000
Change In Accrued Expense	$229,000	$-12,124,000	$2,452,000	$-25,616,000
Change In Payable	$-2,284,000	$-292,000	$-2,791,000	$18,790,000
Change In Account Payable	$-2,284,000	$-292,000	$-2,791,000	$18,790,000
Change In Prepaid Assets	$-2,860,000	$5,453,000	$-620,000	$4,852,000
Change In Receivables	$-7,661,000	$9,707,000	$3,935,000	$4,822,000
Changes In Account Receivables	$-7,661,000	$9,707,000	$3,935,000	$4,822,000
Other Non Cash Items	$13,498,000	$7,425,000	$-95,000	$368,000
Stock Based Compensation	$34,563,000	$38,463,000	$40,267,000	$40,788,000
Provisionand Write Offof Assets	$0	$-5,000,000	$0	$0
Asset Impairment Charge	$0	$2,101,000	$0	$0
Amortization Of Securities	$-5,479,000	$-4,144,000	$687,000	$4,712,000
Depreciation Amortization Depletion	$15,615,000	$16,215,000	$17,320,000	$12,909,000
Depreciation And Amortization	$15,615,000	$16,215,000	$17,320,000	$12,909,000
Gain Loss On Investment Securities	$-62,000	$-6,616,000	$-2,205,000	$79,000
Net Income From Continuing Operations	$-193,878,000	$-227,102,000	$-263,494,000	$-280,321,000

Fetched: 2026-06-17